

Duncan J. Macrae  
David Field  
Jean-Christophe Mercier  
Jens Møller  
Tom Stiris  
Paolo Biban  
Paul Cornick  
Allan Goldman  
Sylvia Göthberg  
Lars E. Gustafsson  
Jürg Hammer  
Per-Arne Lönnqvist  
Manuel Sanchez-Luna  
Gunnar Sedin  
Nim Subhedar

## Inhaled nitric oxide therapy in neonates and children: reaching a European consensus

Received: 8 May 2003  
Accepted: 1 December 2003  
Published online: 13 January 2004  
© Springer-Verlag 2004

Electronic Supplementary Material  
Supplementary material is available in the  
online version of this article at  
<http://dx.doi.org/10.1007/s00134-003-2122-3>

D. J. Macrae (✉)  
Royal Brompton Hospital,  
Sydney Street,  
SW3 6NP London, U.K.  
e-mail: d.macrae@rbh.nthames.nhs.uk  
Tel.: +44-20-73528121  
Fax: +44-20-73518360

D. Field · P. Cornick  
Department of Child Health,  
Leicester Royal Infirmary,  
LE1 5WW Leicester, U.K.

J.-C. Mercier  
Hôpital Robert Debré,  
48 Boulevard Sérurier,  
75935 Paris Cedex 19, France

J. Møller  
Klinikum Saarbrücken,  
Winterberg 1, 66119 Saarbrücken,  
Germany

T. Stiris  
Barn. Afd, Ullevål sykehus,  
0407, Norway

P. Biban  
Neonatal and Paediatric Intensive Care Unit,  
Major City Hospital,

A. Goldman  
Great Ormond Street Children's Hospital,  
Great Ormond Street,  
WC1 N 3JH London, U.K.

S. Göthberg  
Drottning Silvias Barnsjukhus,  
Sahlgrenska University Hospital,  
41685 Gothenburg, Sweden

L. E. Gustafsson  
Department of Physiology  
and Pharmacology,  
Karolinska Institutet,  
17177 Stockholm, Sweden

J. Hammer  
Kinderspital, Roemerstrasse 8, 4005 Basel,  
Switzerland

P.-A. Lönnqvist  
Department of Paediatric Anaesthesia  
and Intensive Care,  
Astrid Lindgren Children's Hospital,  
Karolinska Institutet,  
17176 Stockholm, Sweden

M. Sanchez-Luna  
Servicio de Neonatología,  
Hospital General Universitario  
Gregorio Marañón,  
Dr. Esquerdo 46, 28009 Madrid, Spain

G. Sedin  
Akademiska sjukhuset,  
75185 Uppsala, Sweden

N. Subhedar  
Neonatal Unit,  
Liverpool Women's Hospital,  
Crown Street, L8 7SS Liverpool, U.K.

**Abstract** Inhaled nitric oxide (iNO) was first used in neonatal practice in 1992 and has subsequently been used extensively in the management of neonates and children with cardiorespiratory failure. This paper assesses evidence for the use of iNO in this population as presented to a consensus meeting jointly organised by the European Society of Paediatric and Neonatal Intensive Care, the European Society of Paediatric Research and the European Society of Neonatology. Consensus Guidelines on the Use of iNO in Neonates and Children were produced following discussion of the evidence at the consensus meeting.

**Keywords** Inhaled nitric oxide · Pulmonary hypertension · Persistent pulmonary hypertension of the newborn · Extracorporeal membrane oxygenation · Vasodilator · Pulmonary

Mallinckrodt Hosp. Prods. IP Ltd.  
Exhibit 2006  
Praxair Distrib., Inc. et al., v. Mallinckrodt Hosp. Prods. IP Ltd.  
Case IPR2016-00777

## Introduction

Inhaled nitric oxide (iNO) has been used in Europe to treat a variety of conditions in neonates and children since 1992, foremost in persistent pulmonary hypertension of the newborn (PPHN), which has remained a major therapeutic challenge in the NICU [1, 2]. Introduction of iNO into clinical use was virtually unregulated in Europe, where supplies of industrially produced gas were freely available. Subsequently clinical trials have established roles for iNO therapy in the treatment of term neonates with severe respiratory failure and a pharmaceutical quality product has recently become available in Europe and the United States. The high cost of the licensed product, compared to previous industrial supplies, and the narrow scope of the drug's licensed indications suggested to our group that a consensus should be established on the use of iNO therapy in neonates and children covering both its approved and potential indications.

## Methods

An Advisory Board was established under the auspices of the European Society of Neonatal and Paediatric Intensive Care to coordinate the scientific programme of the meeting. The board consisted of experts with proven scientific or clinical expertise relevant to the clinical use of iNO. The board identified a further panel of experts who were invited to act as section leaders whose role was to review the literature in their designated subject area. Section leaders were asked to produce written summaries of their subject area, which were then circulated to delegates prior to the meeting and which formed the basis of the evidence presented to delegates at the consensus meeting itself.

A further panel of opinion leaders were invited to attend the meeting on the basis of their known interest in the use of iNO or their status as opinion leaders in the field of neonatal and paediatric intensive care. The European Society of Paediatric Research and the European Society of Neonatology were officially represented at the meeting. At the consensus meeting each subject area was presented in summary by the section leader(s), following which open discussion led to the composition of draft consensus statements. These were then edited and re-presented to delegates with further discussion leading to final agreement on the individual consensus statements.

## Results

### Inhaled nitric oxide in term and near-term neonates

Neonatal hypoxaemia may result from *intra-pulmonary shunting*, from *extra-pulmonary shunting* (so-called PPHN) or from cyanotic congenital heart disease. The presence of interstitial pulmonary infiltrates or a low volume lung (<6–7 ribs) on chest X-ray strongly suggests parenchymal lung disease. Alveolar recruitment has been shown to render babies with severe hypoxaemic respira-

unresponsive [2]. Exogenous surfactant and ventilatory manoeuvres [3] should therefore be deployed to optimise lung volume before iNO is introduced. If cyanosis persists after any necessary lung recruitment manoeuvres have been applied, an echocardiogram should be obtained to confirm or exclude the presence of congenital heart disease or pulmonary hypertension as causes of cyanosis. Inhaled NO is most likely to benefit babies with PPHN with recruited lung volume and is unlikely to benefit babies with cyanotic heart disease.

The recent Cochrane Review was used as a framework in this discussion [4]. The review, last updated in December 2000, included 12 relevant trials in its analysis, all of which used random allocation [5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]. One further on-going study received limited analysis since, at the time of review, it was on-going and published only as an abstract [16]. A literature search up to October 2003 failed to reveal any new randomised, controlled trials not already included in the Cochrane review.

The limitations of the studies presented within the Cochrane review were highlighted. Of major importance, the entry criteria differed markedly between trials as did dosage and ventilatory strategies, there being a suggestion that high frequency oscillatory ventilation (HFOV) appears beneficial in achieving a response to iNO [10]. Eight of the 12 clinical trials studied the effect of iNO on the overall clinical course of the babies included and, in particular, whether the need for extracorporeal membrane oxygenation (ECMO) was reduced. Only six trials did not allow crossover [6, 7, 8, 11, 12, 13]. Of the six studies which did not allow crossover, three [6, 11, 12] found a statistically significant reduction in the combined outcome of death or requirement for ECMO in the NO group. A meta-analysis of all six studies found that iNO treatment resulted in a reduction in the incidence of death or requirement for ECMO (relative risk 0.65) [4].

Inhaled nitric oxide therefore appears to improve outcome in hypoxaemic term and near-term infants. The improvement is due mainly to a reduction in the need for ECMO, since mortality was not reduced. The two largest studies [6, 11] included infants with congenital diaphragmatic hernia as sub-groups. A separate analysis has been presented from one of these studies [17]. There was no evidence that outcome was improved in these babies through the use of iNO, even if short-term improvements in oxygenation did occur. It is important to note that whilst iNO reduced the need for ECMO, the majority of mature babies in these studies went on to ECMO.

Only one study has considered long-term follow-up as a primary or secondary hypothesis. In this study, the incidence of disability, the incidence of deafness and infant development scores were all similar between tested survivors who received NO and those who did not [18].

The major randomised, controlled trials of iNO in term

exclude congenital heart disease as a cause of hypoxaemia prior to exposure to iNO. Babies with such lesions are at best unlikely to benefit from iNO, as cyanosis is due to extra-pulmonary shunting. Inhaled NO exposure may even be harmful in some babies with congenital heart disease, such as those with obstructed total anomalous pulmonary venous drainage or severe left ventricular dysfunction with right-to-left ductal shunting [19], in whom pulmonary arteriolar vasoconstriction may be clinically beneficial by reducing left heart filling.

#### *Dosage and response to inhaled nitric oxide treatment in term and near-term neonates*

Decisions regarding continued use of iNO therapy cannot be based on the primary end points used in the pivotal studies, such as reduced mortality or 'avoidance' of ECMO. Instead clinicians must use surrogate physiological end points in order to establish whether an initial test exposure to iNO is effective. Improvement in oxygenation of approximately 20% over baseline values at 30–60 min has been used in many studies as an indicator of early response to iNO including six of the studies in the Cochrane review [5, 6, 7, 9, 11, 12].

Four published studies have reported dose-response data for this group of babies [7, 20, 21, 22]. All four studies suggest that a maximal beneficial effect of iNO is already seen at concentrations of less than 30 ppm. Further increases of iNO (to 80–100 ppm) do not appear to result in further improvement of oxygenation above that achieved at 20–30 ppm. The large NINOS study [11] used initial doses of 20 ppm iNO, but exposed 'partial responders' to 80 ppm. Only 6% of these partial responders were converted to full response by 80 ppm iNO.

In the small study published by Tworetzky et al. a maximum reduction of pulmonary artery pressure was observed at 20 ppm NO, whereas maximal improvement in oxygenation occurred at 5 ppm [23]. Response to the introduction of iNO usually occurs rapidly in 'responders'. Some investigators attribute clinical improvements seen several hours later to iNO administration [24]. However it was the expert group's view that there is a serious danger that babies with very severe hypoxaemia could be harmed if ECMO referral were to be delayed whilst waiting for a 'late' response.

If no substantial effect has been achieved during a trial of iNO, treatment with iNO should be rapidly discontinued or the baby transferred on iNO to a level 3 or tertiary neonatal unit. This should occur as soon as the clinician is convinced that iNO is not inducing a beneficial effect judged by improving oxygenation. The trial to improve oxygenation with NO should not last longer than 4 h. The reason not to prolong NO therapy unnecessarily is that

endogenous NO production. Down-regulation of endogenous NO synthase by the use of iNO has been suggested [25, 26, 27].

We were unable to identify studies establishing the optimal regime for maintenance of iNO therapy once an initial response has been established. It is, however, logical in clinical practice to seek to minimise iNO exposure by lowering the iNO dose, provided the beneficial effects on oxygenation and general clinical stability are maintained. This approach was described by Kinsella et al. [28] in the early stages of the clinical exploration of iNO therapy and further validated by Clark et al. [6].

#### Discontinuation and weaning

Some information is available on strategies for weaning patients from iNO as clinical improvement occurs. In a prospective study, Demirakca et al. evaluated the clinical response to iNO in neonates and children with acute respiratory distress syndrome (ARDS) [21]. Attempts to discontinue iNO were made as soon as a stable respiratory status (PEEP < 6 cmH<sub>2</sub>O, inspiration/expiration ratio of 1:2, FiO<sub>2</sub> < 0.8 and an iNO concentration of 5 ppm) had been achieved. Oxygenation index (OI) values of less than 5 predicted successful withdrawal with a sensitivity of 75%, a specificity of 89%, a positive predicted value of 69% and a negative predictive value of 91% [21].

Aly et al. [29] adopted a weaning strategy for babies with PPHN which included step-wise 5 ppm decrements of iNO doses. Discontinuation of iNO was performed as soon as the patient was stable with an FiO<sub>2</sub> less than 0.5. Weaning was successful at the first attempt in 9 out of 16 patients. In the remaining seven neonates, major signs of deterioration (oxygen saturation drop >10% or below 85%) prompted a reinstatement of iNO treatment for 30 min. Subsequently, FiO<sub>2</sub> was raised by 0.4 and a successful withdrawal of iNO was then obtained. Interestingly, FiO<sub>2</sub> could be returned to the pre-weaning value in a few hours. Sokol et al. [30] noted that significant deterioration of PaO<sub>2</sub> occurred in some babies even when weaned from 1 to 0 ppm, suggesting that iNO is physiologically active even at very low concentrations. There may be a role for other vasodilators such as epoprostenol, iloprost, endothelin antagonists or selective phosphodiesterase inhibitors [31] when weaning babies from iNO after treatment courses of sufficient duration to down-regulate NO synthase.

#### Toxicity

Nitric oxide reacts with oxygen to form nitrogen dioxide (NO<sub>2</sub>) where the reaction rate is proportional to the square

oxygen concentration. Whilst NO itself is a relatively reactive molecule, NO<sub>2</sub> is demonstrably more reactive and toxic and is a radical (it has an unpaired electron). Due to the fact that NO is usually administered in combination with high inhaled oxygen concentrations and that NO<sub>2</sub> in animal experiments is damaging to the lungs already at low concentrations when administered with other oxidants, the main toxicological concern should be focused on NO<sub>2</sub> exposure and this should be kept to a minimum. In long-term exposure lung damage may occur at 0.5 ppm NO<sub>2</sub> and acute lethal effects are seen from 100 ppm. Human subjects inhaling 2–3 ppm NO<sub>2</sub> for 5 h demonstrated reductions in antioxidant defences and an increase in alveolar permeability [32]. Reactive species such as peroxyxynitrite formed from NO<sub>2</sub>, as well as being implicated in short-term toxicity, have the potential to cause damage to DNA, raising the possibility of mutagenic or carcinogenic effects. However, the concentrations of iNO and NO<sub>2</sub> to which patients are exposed clinically are largely within the permitted limits for occupational exposure [33]. There is as yet no evidence that inhalation of NO has any lasting adverse effects. Long-term follow-up of children exposed to iNO therapy will be required to establish any late adverse effect.

When NO reacts with haemoglobin, methaemoglobin (metHb) is formed. MetHb is not directly toxic, but is unable to carry oxygen. If metHb is allowed to accumulate it can significantly reduce the oxygen-carrying capacity of blood. The monitoring and management of metHb during clinical iNO therapy is discussed below.

Inhalation of NO has been shown by some investigators [34], but not by others [35], to inhibit platelet function. The randomised controlled neonatal trials have, however, not shown any difference in bleeding complications between groups administered iNO or control gas [4].

### Delivery and monitoring

Nitric oxide administration systems should deliver constant concentrations of iNO within the respiratory gas mixture independent of ventilator mode or settings, ensure a rapid mixing and minimise contact time between NO and oxygen, thereby reducing the possibility of generating high NO<sub>2</sub> levels [36, 37, 38]. The delivery system should display the pressure within the NO cylinder to permit timely cylinder changes to be undertaken without loss of gas supply. The system should ideally encompass a backup power supply for use in the event of mains failure or during intra-hospital transport. A manual backup or 'hand bagging' facility must be provided for use in the event of ventilator failure or other indications for hand ventilation, as sudden discontinuation of iNO therapy can be life-threatening [36, 37, 39].

The safest approach to iNO delivery is probably to use only pharmaceutical grade NO stored in cylinders and at concentrations and conditions approved by drug regulatory bodies and delivered by devices tested and approved according to the appropriate medical device legislation.

In the clinical setting, measurement of iNO and NO<sub>2</sub> concentrations can be undertaken using chemiluminescence or electrochemical devices. There are a number of practical disadvantages of chemiluminescence analysers in the clinical setting, including their high cost, their need for relatively high sample volumes, noise, their need for regular calibration and their relative inaccuracy in measuring NO<sub>2</sub> due to the "quenching" effect [37]. Electrochemical analysers use two separate fuel cell sensors for NO and for NO<sub>2</sub>, placed either in the gas mainstream or side stream of the ventilatory circuit. Electrochemical devices do not underestimate NO<sub>2</sub> levels, are inexpensive, silent, easy to calibrate and require very low gas sample volumes. Most devices are portable. Electrochemical analysers are, however, relatively insensitive (resolution 0.5 ppm) and their measurements may be affected by temperature, pressure, humidity and the presence of other gases in the environment [37]. Although many early studies of iNO delivery systems were constructed by investigators for their own studies, a number of delivery and monitoring systems have been developed for clinical use and are commercially available [39, 40].

Inhaled NO<sub>2</sub> concentrations should be kept to a minimum. Clinical and experimental evidence show that it is possible to administer 20 ppm iNO whilst generating NO<sub>2</sub> concentrations of less than 0.2 ppm [38]. Direct comparisons with tolerable environmental NO<sub>2</sub> concentrations should take into account that the awake person inhaling NO<sub>2</sub> is exposed to at least 50% lower NO<sub>2</sub> concentrations in their trachea due to efficient scavenging of NO<sub>2</sub> in the upper airways.

Nitric oxide has been supplied for clinical use by a number of suppliers as a compressed gas diluted in a balance of nitrogen with final NO concentrations of between 100 and 1000 ppm. The gas is supplied in aluminium cylinders filled to pressures of 150–200 bar. Very concentrated preparations may be difficult to deliver accurately whilst mixtures with low NO concentrations can reduce FiO<sub>2</sub> excessively [41]. The final choice of cylinder NO concentration will, therefore, depend on the characteristics of the delivery system in use and the required FiO<sub>2</sub> and FiNO. The future availability of iNO as a pharmaceutical within Europe may encourage standardisation.

### Environmental safety

The US National Institute for Occupational Safety and Health (NIOSH) (1998) has estimated that the maximum

NO<sub>2</sub> of 5 ppm and NO 25 ppm over an 8-h period for these potentially toxic substances [33]. Several European countries have regulated maximal occupational exposure to 2 ppm NO<sub>2</sub>. Extrapolating this to the ICU in which iNO would be administered for a 24-h period, it would be prudent to aim for environmental levels of NO<sub>2</sub> in the ICU below 1.5 ppm. Environmental NO contamination can occur from two sources during iNO administration: dumped waste ventilator gas and accidental leakage of concentrated gas from a delivery system or cylinder. The US Food and Drug Administration state, in their specification for medical delivery of NO, that such delivery “does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required” [42]. A similar ruling is applied by the UK National Health Service, which states that scavenging of waste NO is unnecessary provided that ventilation in the ICU meets required standards [43]. Several studies confirm that this advice is sound [44, 45]. There must, however, be a small risk of high environmental levels occurring from uncontrolled release of a large volume of concentrated gas from a cylinder in the event of a serious error or accident. For this reason, the consensus group suggest that it is reasonable to measure environmental levels of NO<sub>2</sub> continuously.

### Transport

In 30–50% of babies given a trial of iNO the therapy does not result in a sustained positive oxygenation response [4]. Most babies who fail to respond to iNO are potential ECMO candidates. Since acute withdrawal of iNO may be associated with severe rebound hypoxaemia, even in babies who apparently respond poorly [46, 47], arrangements must be in place for these babies to be transferred to an ECMO centre without interruption of iNO delivery. Occasionally non-neonates may require transport within or between hospital whilst receiving iNO.

Apart from the ability to deliver iNO safely to the baby during transport, consideration must also be given to safety of the staff and crew within the transport vehicle, and compliance with any regulations governing such use. Kinsella et al. recently reported concentrations of NO and NO<sub>2</sub> in the cabin environment of various transport vehicles during iNO use and confirmed them to be negligible. Furthermore, they calculated the effects of uncontrolled release of a full US D-type NO cylinder containing 350 l NO gas. In this “worst case scenario” environmental NO levels were unlikely to reach dangerous levels (maximum 40 ppm fixed wing aircraft, 34 ppm ground ambulance, 94 ppm small helicopter) [48].

The expert group recommend that equipment for delivery and monitoring of iNO during transport should

and test requirements of the specific aircraft or other transport vehicle used. Several delivery systems have been used during transport and at least two portable systems are commercially available, one of which is specifically designed as a transport system [48].

### Staff training

Clinical use of iNO involves potential hazards for both staff and patients, mainly from the risk of exposure to toxic levels of NO and NO<sub>2</sub>, but also issues such as safe handling of gas cylinders. The safe and appropriate use of medical equipment requires adequate preparation and training. Regulatory authorities frequently recommend standards for training in the use of medical equipment, typically stating that training should include both theoretical and practical instruction [49]. US guidelines for neonatal use recommend physician training [50] and some nursing authors have discussed the need for training [51]. It has also been recommended that protocols or guidelines should be compiled by hospitals using iNO, covering all aspects of its use including responsibility for off-label prescription. Such protocols should aim to help staff deliver iNO therapy that is both safe and effective [52].

### Use of inhaled nitric oxide in preterm neonates

For the purposes of this paper, ‘preterm’ neonates are defined as those babies too premature to be considered for ECMO should their condition require it, i.e. babies less than 34 weeks completed gestation [53].

Inhaled NO may improve oxygenation in preterm neonates with hypoxaemic respiratory failure in one of two ways: (1) it may reverse extra-pulmonary shunting by selectively decreasing pulmonary vascular resistance (PVR) and (2) it may reduce intra-pulmonary shunting (and/or V/Q mismatch) by redistributing pulmonary blood flow. The former mechanism is likely to be the most important in infants with primary or secondary PPHN, whereas the latter will be more important in the majority of preterm infants who have parenchymal lung disease as the primary cause of their hypoxaemic respiratory failure.

There are three published, randomised, controlled trials (RCTs) of iNO therapy in preterm infants [14, 54, 55], overviews of which have been reported in the form of two systematic reviews [53, 56]. A total of 207 infants have been studied in these RCTs. Other RCTs (such as the UK INNOVO trial, NICHD Preemie iNO trial and other US trials) are either on-going or have only just completed recruiting and results are not yet available. One small RCT has reported the long-term neurodevelopmental outcome following iNO therapy [57].

A Cochrane Review has summarised the results of the

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.